[1] Lin D, Wu J. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target[J]. World J Gastroenterol, 2015, 21(42): 12171-12178.
[2] Maniotis A J, Folberg R, Hess A, et al .Vascular channel formation by human melanomcells in vivo and in vitro: vasculogenic mimicry[J] . Am J Pathol, 1999, 155(3): 739-752.
[3] Yu L, Li L. Clinical significance of vasculogenic mimicry expression in human gliomas [J]. Chin J Neuromed, 2014, 13(9): 929-933.
[4] Kirschmann D A, Seftor E A, Hardy K M, et al . Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications[J]. Clin Cancer Res, 2012, 18(10): 2726-2732.
[5] Mihic P D,Ikenberg K, Tinguely M, et al . Tumor cell plasticity and angiogenesis in human melanomas [J] . PLoS One,2012,7 (3): e33571- e33571.
[6] Liu R, Yang K, Meng C, et al . Vasculogenic mimicry is a marker of poor prognosis in prostate cancer.[J]. Cancer Biol & Ther, 2012, 13(7):527-533.
[7] Hirasawa T, Miazawa M ,Yasuda M, et al . Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamyc in (mTOR) suppression in ovarian clear cell adenocarcinoma: in vitro explorations for clinical trial[J].Int J Gynecol Cancer, 2013, 23(7): 1210-1218.
[8] 陈洪菊, 唐彬秩, 屈 艺,等. mTOR信号通路调节HIF-1α及VEGF[J]. 生命的化学, 2011, 31(6): 838-843.
[9] 李 星. NF-κB和HIF-1α在前列腺癌中的表达及意义[D].郑州:郑州大学, 2013.
[10] Lee S H, Kim M H, Han H J. Arachidonic acid potentiates hypoxia-induced VEGF expression in mouse embryonic stem cells: involvement of Notch, Wnt. and HIF-lalpha[J]. Am J Physiol Cell Physio1, 2009, 297(1): C207-C216.
[11] Newman A C, Hughes C C. Macrophages and angiogenesis: a role for Wnt signaling[J]. Vase Ce11, 2012, 4(1):13.
[12] Nagaraj N S, Datta P K. Targeting the transforming growth factor-beta signaling pathway in human cancer [J]. Expert Opin Investig Drugs, 2010, 19(1): 77-91.
[13] De Luca A, Maiello M R, D'Alessio A, et al . The RAS/RAF/MEK /ERK and the PI3K /AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches[J]. Expert Opin Ther Targets, 2012, 16(2):17-27.
[14] 陈 凯, 孙慧燕, 牟心红,等. TGF- β/Smad及TGF- β/MAPK介导肿瘤细胞凋亡的机制[J]. 武警后勤学院学报(医学版), 2012, 21(2):144-146.
[15] Kong C S,Kim K H,Choi J S, et al . Salicin,an extract from white willow bark, inhibits angiogenesis by blocking the ROS -ERK pathways [J]. Phytother Res, 2014, 28(8): 1246-1251.
[16] Leelahavanichkul K, Amornphimoltham P, Molinolo A A, et al . A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis[J]. Mol Oncol, 2014, 8(1): 105-118.
[17] Shyu K G, Lin S, Lee C C, et al . Evodiamine inhibits in vitro angiogenesis: implication for antitumorgenicity [J]. Life Sci, 2006, 78(19):2234-2243.
[18] Brown K A, Pietenpol J A, Moses H L. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling[J]. J Cell Biochem, 2007, 101(1): 9-33.
[19] Laughner E, Taghavi P, ChilesK, et al . HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 (HIF-1) synthesis:novel mechanism for HIF-1-mediated vascular endothelial growth factor expression[J]. Mol & Cell Biol, 2001, 21(12): 3995-4004.
[20] 费洪荣,王凤泽. PI3K/Akt信号通路的调控与肿瘤血管生成[J].生命的化学, 2010,30(1): 38-41.
[21] Hong T M, Chen Y L, Wu Y Y. et al . Targeting neuropilin-1 as an antitumor strategy in lung cancer[J]. Clin Cancer Res, 2007, 13(16):1759-4768.
[22] Hermanov A M, Trna J , Nenuti L R , et al . Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions [J] . Eur J Gastroenterol Hepatol, 2008, 20(8): 732-739.
[23] Imada T, Matsuoka J, Nobuhisa T, et al . COX-2 induction by heparanase in the progression of breast cancer.[J]. Int J Mol Med, 2006, 17(2):221-228.
[24] Sun T, Zhao N, Zhao X L, et al . Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry [J]. Hepatology, 2010, 51(2):545-556.
[25] 司瑞丽,李晓凤. 缺氧诱导因子1与肿瘤相关性的研究进展[J]. 医学综述, 2016, 22(7):1287-1291.
[26] Cai T Y, Liu X W, Zhu H, et al . Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α.[J]. Mol Cancer Ther, 2014, 13(3):630-642.
[27] Semenza G L. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells[J]. Trends Mol Med, 2012, 18 (9): 534-543.
[28] Zhang J T, Sun W, Zhang W Z, et al . Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway[J]. BMC Cancer 2014,14 (1): 193-210.
[29] 冯世杰,马秀娟,宗 英, 等. 低氧诱导因子-1的病理生理及相关药物研究进展[J]. 药学实践杂志,2014, 32(3):161-166.
[30] Langlois B, Perrot G, Schneider C, et al . LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways [J]. PLoS One, 2010, 5(7): e11584.
[31] Serwe A, Rudolph K, Anke T, et al . Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol [J]. Invest New Drug, 2012, 30(3): 898-915.
[32] Lee H, Kim J S, Kim E. Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways[J]. PLoS One, 2012, 7(11): e50624.
[33] 张 平, 许霞辉, 贺兼斌, 等. 人参皂苷Rg3联合苏拉明通过下调TGF-β 1表达抑制小鼠肺癌生长转移[J]. 现代生物医学进展, 2013, 13(21): 4039-4043.
[34] Gu J C, Yu W B, Wang Y, et al . Effects of astragalus polysaccharides on tumor growth and the expression of HSP70 in transplanted breast cancer for MA891 in TA2 mice abstract [J]. CJCPT, 2006, 13 (20):1534-1537.
[35] Tin MM, Cho CH, Chan K, et al . Astragalussaponins induce growth inhibition and apoptosis in human colon cancer cellsandtumorxenograft[J] . Carcinogenesis, 2007, 28(6): 1347-1355
[36] 庄 钦,毛 威. 丹参多种活性成分调节血管新生机制的研究概述[J]. 浙江中医药大学学报, 2014(4): 506-510.
[37] 李 妍,杨维泓,徐玉芬,等. 姜黄素对Lewis肺癌小鼠TGF-β 1 信号转导通路的影响[J]. 中华中医药学刊,2013,31(1):138-141.
[38] Chen W, Lu Y, Wu J, et al . Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis [J]. Cancer Chemoth Pharm, 2011, 67(4):799-808.